Peer-Reviewed Publications

      Modeling the population health impact of introducing a Modified Risk Tobacco Product into the U.S. market

      Djurdjevic, S.; Lee, P. N.; Weitkunat, R.; Sponsiello-Wang, Z.; Lüdicke, F.; Baker, G.

      Published
      May 16, 2018
      DOI
      10.3390/healthcare6020047
      PMID
      29772688
      Link to publication
      Topic
      Summary

      Philip Morris International (PMI) has developed the Population Health Impact Model (PHIM) to quantify, in the absence of epidemiological data, the effects of marketing a candidate modified risk tobacco product (cMRTP) on the public health of a whole population. Various simulations were performed to understand the harm reduction impact on the U.S. population over a 20-year period under various scenarios. The overall reduction in smoking attributable deaths (SAD) over the 20-year period was estimated as 934,947 if smoking completely went away and between 516,944 and 780,433 if cMRTP use completely replaces smoking. The reduction in SADs was estimated as 172,458 for the World Health Organization (WHO) 2025 Target and between 70,274 and 90,155 for the gradual cMRTP uptake. Combining the scenarios (WHO 2025 Target and cMRTP uptake), the reductions were between 256,453 and 268,796, depending on the cMRTP relative exposure. These results show how a cMRTP can reduce overall population harm additionally to existing tobacco control efforts.

      Related Publications

      Influence of tobacco smoking on the development of halitosis

      Clinical

      Tobacco harm reduction: The potential to reduce the risk from smoking: a six-month exposure response study on switching from cigarettes to tobacco heating system (THS)

      Clinical

      Methodology for monitoring adverse event reports for potential modified risk tobacco products: Experience at Philip Morris International

      Clinical

      Biomarker of exposure level data set in smokers switching from conventional cigarettes to Tobacco Heating System 2.2, continuing smoking or abstaining from smoking for 5 days

      Clinical

      Evaluation of biological and functional changes in healthy smokers after switching from cigarettes to Tobacco Heating System (THS) 2.2 for 6 months

      Clinical

      Evaluation of biological and functional changes in healthy smokers switching to the Tobacco Heating System 2.2 versus continued tobacco smoking: Protocol for a randomized, controlled, multicenter study

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.